Bio-Rad Laboratories, Inc.
BIOB
$279.91
-$58.64-17.32%
| Weiss Ratings | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.84 | |||
| Price History | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -17.32% | |||
| 30-Day Total Return | -15.74% | |||
| 60-Day Total Return | -11.78% | |||
| 90-Day Total Return | -8.45% | |||
| Year to Date Total Return | -12.71% | |||
| 1-Year Total Return | -39.69% | |||
| 2-Year Total Return | -46.17% | |||
| 3-Year Total Return | -53.42% | |||
| 5-Year Total Return | -8.67% | |||
| 52-Week High % Change | -40.18% | |||
| 52-Week Low % Change | 3.29% | |||
| Price | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $467.95 | |||
| 52-Week Low Price | $271.00 | |||
| 52-Week Low Price (Date) | Oct 27, 2023 | |||
| 52-Week High Price (Date) | May 04, 2023 | |||
| Valuation | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.98B | |||
| Enterprise Value | 7.78B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -21.50 | |||
| Earnings Per Share Growth | -82.27% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.02 | |||
| Price/Book (Q) | 0.91 | |||
| Enterprise Value/Revenue (TTM) | 2.92 | |||
| Price | $279.91 | |||
| Enterprise Value/EBITDA (TTM) | 15.63 | |||
| Enterprise Value/EBIT | 22.08 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 28.82M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 724 7000 | |||
| Address | 1000 Alfred Nobel Drive Hercules, CA 94547 | |||
| Website | www.bio-rad.com | |||
| Country | United States | |||
| Year Founded | 1952 | |||
| Profitability | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 13.23% | |||
| Profit Margin | -23.85% | |||
| Management Effectiveness | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.71% | |||
| Return on Equity | -- | |||
| Income Statement | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.67B | |||
| Total Revenue (TTM) | 2.67B | |||
| Revenue Per Share | $92.70 | |||
| Gross Profit (TTM) | 1.43B | |||
| EBITDA (TTM) | 499.50M | |||
| EBIT (TTM) | 353.60M | |||
| Net Income (TTM) | -637.32M | |||
| Net Income Avl. to Common (TTM) | -637.32M | |||
| Total Revenue Growth (Q YOY) | -6.72% | |||
| Earnings Growth (Q YOY) | -57.75% | |||
| EPS Diluted (TTM) | -21.50 | |||
| EPS Diluted Growth (Q YOY) | -56.32% | |||
| Balance Sheet | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.61B | |||
| Cash Per Share (Q) | $55.77 | |||
| Total Current Assets (Q) | 3.05B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.74B | |||
| Current Ratio (Q) | 5.831 | |||
| Book Value Per Share (Q) | $306.51 | |||
| Total Assets (Q) | 12.30B | |||
| Total Current Liabilities (Q) | 522.80M | |||
| Total Debt (Q) | 1.41B | |||
| Total Liabilities (Q) | 3.56B | |||
| Total Common Equity (Q) | 8.74B | |||
| Cash Flow | BIOB - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 20.21M | |||
| Cash from Financing (TTM) | -425.65M | |||
| Net Change in Cash (TTM) | -30.18M | |||
| Levered Free Cash Flow (TTM) | 134.77M | |||
| Cash from Operations (TTM) | 374.90M | |||
